July 20, 2022
Servier Affirms Commitment to Cancer by Announcing the Opening of a Global R&D Center and Expanded Offices in Boston's Seaport
June 1, 2022
Servier to Showcase Growing Oncology Portfolio at the ASCO and EHA 2022 Annual Meetings
May 25, 2022
Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia
April 21, 2022
Phase 3 AGILE Data of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia Published in the New England Journal of Medicine
March 17, 2022
Servier Joins Everest Climb to Fight Cancer Benefitting Fred Hutchinson Cancer Research Center
March 10, 2022
Servier Submits a Marketing Authorization Application to the European Medicines Agency (EMA) for TIBSOVO® (ivosidenib tablets) for Patients with IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma
March 7, 2022
Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia
Jan 18, 2022
Servier Group Reports Financial Year 2020/2021 Annual Results, R&D Strategy and Pipeline
Dec 11, 2021
Phase 3 Data Demonstrate TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine Significantly Improves Event-Free Survival and Overall Survival in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia
Nov 4, 2021
New Data at ASH 2021 Reinforces the Strength of Servier’s Hematology Portfolio
Aug 25, 2021
Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in IDH1-Mutated Cholangiocarcinoma
Aug 2, 2021
Servier Announces Positive Topline Data from the Global Phase 3 Study of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia

More from Servier

Research & Development

We invest in innovative research and development through our own development or partnerships to best address the unmet needs of patients.

Learn More

Clinical Trials

We strive to have consistent and concise transparency throughout all our clinical trials and research and development for the benefit of our patients.

Learn More

About Us

Servier Pharmaceuticals is a privately held pharmaceutical company focused on oncology. Everything we do is to bring the promise of tomorrow to the patients we serve.

Learn More